Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
收藏官方服务：
资源简介：
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
应用场景：
创建时间：
2021-06-01
相关数据集
DataSheet_3_Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial.pdf
Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in parti
NIAID Data Ecosystem50
Characteristics of the study groups.
Influenza is especially dangerous for high-risk patients, for whom various vaccination strategies are used to prevent this disease. This study assessed the safety and immunological effectiveness of an
Figshare2025-09-18 更新20
DataSheet_1_Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents.pdf
IntroductionTwo doses of inactivated SARS-CoV-2 vaccine CoronaVac cannot elicit high efficacy against symptomatic COVID-19, especially against the Omicron variant, but that can be improved by a third
NIAID Data Ecosystem10
Evaluation of the immunogenicity of live-attenuated influenza vaccines in nasal epithelial cells in primary differentiated human nasal epithelial cells [RNA-Seq]
The host innate immune response to influenza virus is a key determinant of pathogenic outcomes and long-term protective responses against subsequent exposures. Comparison of the transcriptional profil
NIAID Data Ecosystem30
Correlation between overall and influenza-specific humoral immune response variables following influenza vaccination.
aSpearman’s rank r bOnly correlations with p-values below or equal to 0.05 are presented cInfluenza A/H1N1-specific memory-like IgG B cell ELISPOT response Correlation between overall and influenza-sp
NIAID Data Ecosystem10
